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Summary
Objectives: The recognized benefits of administering vaccines simultaneously has
encouraged vaccine producers to develop combination vaccines. If contemporary
research and development can realize vaccines that achieve the current standards for
safety, immunogenicity, and efficacy, other specific vaccine associations may also
merit reconsideration as combination vaccines.
Methods: An historical review of the vaccine association literature reveals two
important themes: first, the programs of mass vaccination, in particular, the eradica-
tion of smallpox, sessions where multiple vaccines (other than the smallpox vaccine)
were given concurrently, and the Expanded Programme on Immunization (EPI); and,
second, the domain of travel vaccines, including travellers to a disease-endemic
country (such as migrants, tourists, military personnel, or expatriates) and WHO
requirements for international travellers.
Results/conclusions: Based on this historical review, combination vaccines worth
reconsideration could fill epidemiologic niches in the EPI with, for instance, a
measles—yellow fever, a measles—Japanese encephalitis or a pertussis-based pae-
diatric combination rabies vaccine. Furthermore, other combinations could broaden
protection against the pathogens responsible for meningitis, pneumonia, or enteric* Corresponding author. Tel.: +33 1 41 02 79 59; fax: +33 1 41 02 75 34.
E-mail address: fletchm@wyeth.com (M.A. Fletcher).
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In the simultaneous administration of associated
vaccines, a person receives two or more vaccines
at the same time, usually in different anatomic
sites. Although this frequently requires additional
injections,1 parents often strive to keep their
family’s immunizations up to date, even if this
means taking their children to numerous vaccination
sessions.2 Likewise, a person travelling to a disease-
endemic area may accept multiple injections in
order to reside under the best possible circum-
stances.3
Besides the need for multiple administrations,
another issue for vaccine associations is the possi-
bility of interactions between the immune res-
ponses.4 In the best case, association enriches the
immune response which may enhance the protec-
tive efficacy. This occurs, for instance, with the
simultaneous administration of the inactive and
the live forms of the poliovirus vaccines,5 and this
phenomenon has also been reported during the
clinical development of influenza virus vaccines.6,7
In the worse case, however, a vaccine in association
with another displays poorer immunogenicity than
the same vaccine administered alone. When asso-
ciating live virus vaccines, studies recommend that
there be an interval of 30 days between the differ-
ent vaccines to limit any possible interference.8
Immunization against different transmissible dis-
eases through simultaneous injections during the
same vaccination session began in the 1930s.9,10
Subsequently there has been important vaccine
research and development allowing health autho-
rities to continue to enlarge the list of vaccine-
preventable diseases. Many of these newly licensed
vaccines have found a place in established immuni-
zation schedules and new vaccines continue to
appear for consideration by paediatric vaccination
programs, both in industrialized and in developing
countries.11,12 In industrialized countries new vac-
cine arrivals have included the hepatitis A virus
vaccine, the rotavirus vaccine, the varicella-zoster
virus (VZV) vaccine, the Streptococcus pneumoniae
capsular polysaccharide (CPS)—carrier protein con-
jugate vaccine, and the Neisseria meningitidis ser-
ogroup C CPS—carrier protein conjugate vaccine.
Furthermore, combinations of the measles virus
vaccine with a rubella virus or amumps virus vaccineare commonly used in industrialized countries,
and are becoming routine in some developing
countries.13,14
In the developing world, the Global Alliance for
Vaccines and Immunization (GAVI) strives to vacci-
nate children against multiple infectious agents
during a few vaccination sessions, in fostering the
work of the Expanded Programme on Immunization
(EPI).15 Through the EPI, clinical trials or demon-
stration programs are performed to introduce vac-
cines, including those against invasive Haemophilus
influenzae type b (Hib) disease,16,17 Japanese ence-
phalitis (JEV),18 yellow fever,19 invasive N. menin-
gitidis disease,20 or rabies,21 into local programs
according to specific epidemiological concerns. In
the absence of appropriate combination vaccines,
these introductions add new injections to the immu-
nization schedule and may add new sessions to the
vaccination program.
The combination vaccines that are currently
available were first introduced as simultaneously
administered individual vaccines. The person
administering an extemporaneous combination vac-
cine mixes the different vaccine valences, either in
the same syringe (e.g. the by-pass syringe) or in the
same vial, just before injection. In contrast to an
association of different vaccines, a combination
vaccine is a single product. Combination or extem-
poraneous combination vaccines benefit from reg-
ulatory approval only upon completion of a full
program of pharmaceutical and clinical develop-
ment.22
The purpose of this paper is to review the vaccine
association literature from an historical perspective
to suggest potential combination vaccines that, in
the light of current vaccine technology, might merit
reconsideration.Materials and methods
The electronic database Medline from 1966 to
2003 was searched using the keywords ‘vaccination’
(or ‘immunization’) and ‘association’ (or ‘simulta-
neous’, or ‘concomitant’). From over 2000 refer-
ences initially obtained, the focus was narrowed to
public health programs with established vaccines
(i.e. clinical trials or demonstration projects).
Vaccine associations were excluded if they haddiseases. Nevertheless, complex issues such as necessity, feasibility, or affordability
will ultimately determine if any one of these becomes a combination vaccine.
# 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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Table 1 Important themes in the vaccine association literature.
Programs of mass vaccination The eradication of smallpox
Sessions where multiple vaccines (other than smallpox vaccine)
were given concurrently
The Expanded Programme on Immunization
Travel vaccines Travellers to a disease-endemic country (such as migrants,
tourists, military personnel, or expatriates)
WHO requirements for international travellerssubsequently become licensed vaccines, for exam-
ple, the paediatric combinations that were initially
based on diphtheria toxoid and tetanus toxoid—
whole-cell Bordetella pertussis vaccine (DTwcP).
A hand search of the reference list of each article
obtained was also conducted.Results
Vaccinology is rich in examples of clinical trials and
of field studies of simultaneous immunizations
against multiple infectious pathogens.23 As noted
in Table 1 it may be helpful to sub-divide the vaccine
association literature into two groups: the programs
of mass vaccination and travel vaccines. These pro-
grams of mass vaccination describe situations ran-
ging from the eradication of smallpox to the EPI
vaccination sessions. The domain of travel vaccines
encourages vaccine associations to provide optimal
protection to travellers to a disease-endemic region,
which might include migrants, tourists, military per-
sonnel, or expatriates.
The programs of mass vaccination
The eradication of smallpox
During the campaign that eradicated smallpox, pub-
lic health workers intensively targeted all age
groups for vaccinia vaccine immunization. Further-
more, the vaccinia vaccine was administered con-
currently with paediatric vaccines like DTwcP, the
oral poliovirus (OPV) vaccine, the BCG vaccine
against tuberculosis, or the measles virus vac-
cine.24—26 Children in Nigeria, for instance, received
a smallpox vaccine, a DTwcP vaccine, a measles
virus vaccine, and a yellow fever virus vaccine
simultaneously.27 The vaccinia vaccine also was
given concomitantly with vaccines matched to a
local epidemiology, like the yellow fever virus vac-
cine28,29 or measles virus vaccine.30,31 Children vac-
cinated against smallpox under field conditions of
mass vaccination in Africa received simultaneous
immunizations against both measles and against
yellow fever.32,33. Furthermore, investigators inthe former Soviet Union reported giving the small-
pox vaccine in association with vaccines against
plague, tick-borne encephalitis (TBE), tularaemia,
or typhus.34 Russian military recruits received con-
comitant tuberculosis, smallpox, typhoid fever, and
tetanus vaccines.35
Sessions where multiple vaccines (other than
smallpox vaccine) are given concurrently
There have been programs of mass vaccination on
the African continent36 and in the former Soviet
Union,37 where multiple vaccines were adminis-
tered concurrently. For instance, a group of Nigerian
children received four vaccines by association: the
OPV vaccine, the measles virus vaccine, the N.
meningitidis serogroups A and C polysaccharide
(Men A/C PS) vaccine, and a killed, whole-cell S.
typhi vaccine.38 In similar circumstances, children
in Sudan received the BCG vaccine in association
with a combination vaccine that had been mixed
just before injection and contained the measles
virus vaccine, diphtheria toxoid and tetanus toxoid,
the inactivated poliovirus (IPV) vaccine, and the
Men A/C PS vaccine.36 A paper from investigators
in the former Soviet Union describes the concomi-
tant administration of a S. typhi toxoid vaccine
(‘TABTe’, tetravalent tetanus, typhoid, and
paratyphoid A and B) with immunizations against
TBE, smallpox, tularaemia, influenza, and tubercu-
losis.39 Another publication documented the con-
current administration of the whole-cell S. typhi
vaccine, with the N. meningitidis serogroup A poly-
saccharide (Men A PS) vaccine (mixed with
diphtheria toxoid), normal human immune globulin
(for hepatitis A prophylaxis), and a vaccine against
influenza.37
The Expanded Programme on Immunization (EPI)
The 27th World Health Assembly established the EPI
in Geneva in 1974 aiming to protect children against
potentially mortal infectious diseases of childhood
through immunization in infancy with BCG, OPV, and
DTwcP vaccines.40 The EPI added the hepatitis B
virus (HBV) vaccine in 1992. Vaccination sessions are
scheduled at birth and then at the ages of 6, 10, and
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Table 2 Vaccine associations investigated within the Expanded Programme on Immunization.
Measles virus Hepatitis
B virus
Measles virus +
hepatitis B virus
Other EPI
vaccine targets
Japanese encephalitis virus Tseng, 199970 N.D. Yuan, 198969 Intralawan, 199118;
Rojanasuphot, 199298
Yellow fever virus Lhuilier, 198965;
Mouchon, 199067;
Soula, 199168;
Coursaget, 199599;
Adu, 199666;
Stefano, 199964
Yvonnet, 1986100;
Yvonnet, 1986101
Coursaget,
199599
N.D.
Rabies virus N.D. N.D. N.D. Lang, 199760,a
Neisseria
meningitidis,
serogroup
A or C
Ajjan, 197881;
Lapeyssonnie, 1979102;
Greenwood, 1981a82;
Omer, 198636
N.D. N.D. Omer, 198636;
Yuan, 1990103,b
N.D. none described.
a DTwcP-IPV vaccine, proposed for the primary series vaccination against childhood infections.
b BCG vaccine against tuberculosis.
NB, a vaccine association for measles, meningococcal meningitis A, and tetanus has been demonstrated, Greenwood, 1981a82 &
Lapeyssonie, 1979102, as well as a vaccine association to prevent hepatitis B, yellow fever, and poliomyelitis, Coursaget, 199599.14 weeks. Furthermore, infants receive the measles
virus vaccine when they reach nine months of age,
often in association with the yellow fever virus
vaccine. This has been incorporated since the
inclusion of this vaccine in 1988 into the EPI of
yellow fever-endemic areas of South America and
Africa.
Beginning in the 1970s, investigators in the devel-
oping world explored novel associations or even
combinations of EPI vaccines (Table 2). For instance,
some replaced OPV with IPV, and a DTwcP—IPV
combination vaccine was tested.41,42 Attempts wereTable 3 Vaccine associations based on yellow fever virus, Sa
travellers to a disease-endemic country (e.g. migrants, tou
Yellow fever virus
Salmonella typhi Ambrosch, 1991112;
Gapochko, 199134;
Ambrosch, 1994113
Hepatitis A virus Receveur, 1993108;
Bienzle, 1996104;
Gil, 1996109; Dumas,
1997110; Bovier, 199911
Bock, 2000107
Japanese encephalitis virus N.D.
Rabies virus N.D.
Neisseria
meningitidis,
serogroup A or C
N.D.
Tick-borne encephalitis virus N.D.
Vibrio cholerae N.D.
N.D. none described; NB, a vaccine association for hepatitis A, ty
1997110.made to administer, during the primary series, the
DTwcP vaccine or the candidate DTwcP—IPV vaccine
concomitantly with the measles virus vaccine.43—48
But this association was ultimately abandoned. Chil-
dren needed to be vaccinated against diphtheria,
tetanus, and pertussis at the youngest possible age,
but the immunogenicity of the measles virus vaccine
tended to be poor in children vaccinated before at
least nine months of age, in part due to remaining
maternal antibodies.
Clinical studies in the early 1990s associated the
measles virus vaccine (or the measles-mumps-lmonella typhi, or hepatitis A virus vaccine, intended for
rists, military personnel, or expatriates).
Salmonella typhi Hepatitis A virus
— —
1;
Bienzle, 1996104;
Vodopija, 1997105;
Van Hoecke, 1998106;
Bock, 2000107
—
N.D. Bock, 2000107
Fritzell, 1992114 Bock, 2000107
Khoo, 1995115 N.D.
Gapochko, 199134 N.D.
Kollaritsch, 1996116 Bienzle, 1996104
phoid fever, and yellow fever has been demonstrated, Dumas,
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Table 4 Vaccine associations intended for travellers to a disease-endemic country (e.g. migrants, tourists, military
personnel, or expatriates), which have been administered simultaneously with adult booster vaccine targets (e.g.
diphtheria and tetanus, poliomyelitis, or influenza).
Diphtheria/tetanusa Poliomyelitis Diphtheria/tetanus/
poliomyelitis
Influenza
Yellow fever virus Wolga, 1986117;
Philipps, 1996118
Wolga, 1986117 N.D. Goullin, 1993119
Hepatitis A virus Bock, 2000107 Bock, 2000107 N.D. N.D.
Salmonella typhi N.D. Clasener, 1967120;
Drabo, 1996121;
Nejmi, 1997122
Petterschmitt, 1991123 N.D.
Tick-borne encephalitis virus Schabet, 1989124 N.D. N.D. N.D.
N.D. none described.
a Diphtheria/tetanus refers to diphtheria toxoid and tetanus toxoid given individually, in association, or by combination.
NB, a vaccine association for typhoid fever, cholera, and poliomyelitis has been demonstrated, Kollaritsch, 1996116.rubella vaccine) with the hepatitis B virus vaccine in
childhood.49—51
Travel vaccines
Travellers to a disease-endemic country
(including migrants, tourists, military personnel,
or expatriates)
Anyone entering a region endemic for a vaccine-
preventable disease often quickly needs to update
their immunization record.52,53 Consequently, the
immunization of travellers is an active arena for
concomitant vaccinations. Judging from the studies
appearing in the vaccine literature, three pairs of
vaccine associations predominate for pre-travel
vaccinations: the hepatitis A vaccine plus the yellow
fever vaccine, the hepatitis Avaccine plus one of theTable 5 Some vaccine indications that could drive developm
Programme on Immunization or within industrialized countr
Indications Region
EPI vaccine targets plus rabies EPI — selected
countries of Africa
Asia and South Am
Bacterial meningitis or
bacterial pneumonia
Both EPI and
industrialized coun
Measles plus yellow fever EPI — selected cou
Africa and South A
Measles plus Japanese encephalitisa EPI — selected cou
Enteric pathogen infections Both EPI and
industrialized coun
a Each as live attenuated virus vaccines.S. typhi vaccines, or the yellow fever vaccine plus a
S. typhi vaccine (Table 3). The hepatitis A vaccine
has also been given concomitantly with vaccines
against other possible travellers’ diseases, such as
Japanese encephalitis, rabies, or cholera (Table 3).
Likewise, typhoid fever vaccines have been adminis-
tered simultaneously with vaccines against rabies,
invasive meningococcal disease (serogroups A and
C), tick-borne encephalitis, or cholera (Table 3).
The former Soviet Union tested binary associa-
tions of vaccines for diseases as varied as TBE,
typhus, plague, typhoid fever, or yellow fever.34,39,54
Travel vaccinations also complete a traveller’s
standard adult booster schedule with diphtheria
toxoid and tetanus toxoid inoculations, with
IPV vaccine, or with an influenza virus vaccine
(Table 4).55 Once again, the yellow fever virusent of new combination vaccines, within the Expanded
y vaccination programs.
Examples of possible
combination vaccines
,
erica
Diphtheria and tetanus
toxoids—B. pertussis
vaccine—hepatitis B virus
vaccine—rabies virus vaccine
tries
H. influenzae type b CPS
conjugate vaccine—N.
meningitidis CPS-carrier
protein conjugate vaccine—S.
pneumoniae CPS conjugate vaccine
ntries of
merica
Measles virus vaccine—yellow
fever virus vaccine
ntries of Asia Measles virus vaccine—Japanese
encephalitis virus vaccine
tries
S. typhi vaccine—V. cholerae vaccine
Hepatitis A virus vaccine—S. typhi
vaccine
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A virus vaccine has been the most commonly
tested association with these standard adult booster
vaccines.
WHO requirements for international travellers
The WHO International Health Regulations for inter-
national travellers have included vaccinations
against yellow fever or against cholera.56,57 The
only formal contra-indication to associated immu-
nizations had been the simultaneous injections of a
killed, whole-cell V. cholerae vaccine with a live
attenuated yellow fever virus vaccine because the
immune response to yellow fever appeared to be
suppressed.56,58 Although these initial claims for
interference have not been substantiated,59 the
WHO no longer recommends the killed, whole-cell
V. cholerae vaccines and they are seldom used.Discussion
Specific vaccine associations that should
drive the development of future
combination vaccines
Based on the vaccine associations that appeared in
the literature, five sets of vaccine associations
might drive the development of future combination
vaccines (Table 5): EEPPI vaccine targets plus rabies;
 bacterial meningitis or bacterial pneumonia;
 measles plus yellow fever;
 measles plus Japanese encephalitis; or
 enteric pathogen infections.I vaccine targets plus rabies
In Asia investigators gave the rabies virus vaccine
concurrently with a paediatric combination,
DTwcP—IPV, in order to protect children against
rabies before the age they would begin to walk
and might become the target of animal bites.60
Bacterial meningitis or bacterial pneumonia
Many investigators have attempted to prevent bac-
terial meningitis or bacterial pneumonia in at-risk
populations by the association of appropriate vac-
cines. For instance, some have combined the CPS—
carrier protein conjugate vaccine for Hib with the
CPS vaccines for N. meningitidis serogroup A + C and
for S. pneumoniae (23 serotypes) in a single injec-
tion.61 Subsequent CPS—carrier protein conjugation
technology has produced new paediatric vaccines
like the N. meningitidis serogroup C conjugate vac-cine and the 7-valent S. pneumoniae conjugate
vaccine.62 As vaccine associations of the past are
often forerunners of combination vaccines of the
future, work is now underway to protect children
against multiple bacterial causes of invasive disease
by combining different CPS-carrier protein conju-
gate vaccines.
Measles plus yellow fever
The measles virus vaccine was frequently given in
association with the yellow fever virus vaccine for
children in vaccination campaigns conducted in
Africa in the 1980s and the 1990s.63—66 The intro-
duction of a measles virus vaccine—yellow fever
virus vaccine combination into the EPI at nine
months of age, which had undergone extensive
clinical development during several years until it
was discontinued, seems worth reviving.65—67
Measles plus Japanese encephalitis
The Japanese encephalitis virus (JEV) vaccine also
has been associated with the vaccines of the EPI,
and in particular with the measles (or the measles-
mumps-rubella) vaccine.18,69,70 Mirroring the
imperative for a measles virus—yellow fever virus
vaccine combination for Africa and Latin America,
the EPI in Asia might welcome a combination against
measles and Japanese encephalitis, with each as a
live attenuated virus vaccine.
Enteric pathogen infections
Hepatitis A virus vaccine—S. typhi Vi polysaccharide
vaccine combinations have recently been devel-
oped.71,72 The cholera vaccine and typhoid vaccine
association continues to be explored in the guise of
live attenuated vaccine candidates.73,74
Specific vaccine associations that are
unlikely to become combination vaccines
By contrast it seems doubtful that three other sets
of vaccine associations will lead to the development
of combination vaccines: measles plus EPI vaccine targets (other than yel-
low fever); measles plus invasive meningococcal disease; or
 influenza plus pneumococcal pneumonia.Measles plus EPI vaccine targets (other than
yellow fever)
For hepatitis B endemic regions it is essential
to initiate hepatitis B vaccination at birth.75,76 A
slight possibility remains that a measles—hepatitis B
combination vaccine could be used for the hepatitis
334 M.A. Fletcher et al.B booster vaccination at nine months of age. On the
other hand, it is unlikely that a combination DTwcP—
measles vaccine to be given at the nine-month-old
visit could be developed for the EPI.77—80
Measles plus invasive meningococcal disease
In Africa a simultaneous measles and meningococcal
meningitis vaccination has been attempted, espe-
cially during epidemics due to N. meningitidis ser-
ogroup A.81,82 By contrast, the recently developed
N.meningitidis serogroup CCPS—carrier protein con-
jugate vaccine is effectivewhen administered before
the age of the recommended measles virus vaccina-
tion, so the meningococcal meningitis vaccination
has already entered theprimary series immunization
schedule for children of some industrialized coun-
tries.83 Furthermore, quadrivalent N. meningitidis
CPS—carrier protein conjugate vaccines (serogroups
A, C, W-135, and Y) and meningococcal serogroup B
vaccines are under development.62 Consequently, a
N. meningitidis—measles virus vaccine combination
is unlikely to be developed.
Influenza plus pneumococcal pneumonia
Among elderly populations, S. pneumoniae super-
infections pose a particularly risky sequel to an
influenza virus infection. Hence, clinicians and ger-
iatric medical specialists have advocated the asso-
ciation of the influenza virus vaccine with a S.
pneumoniae capsular polysaccharide vaccine (23
serotypes) among at-risk populations.84,85 The cur-
rent scheduling of these two vaccinations, which is
yearly for the influenza vaccine but might be five to
ten years later for a second pneumococcal pneumo-
nia vaccination, would seem to preclude develop-
ment of a manageable combination vaccine.86Conclusions
The pace of vaccine research and development con-
tinues unabated leaving health authorities with the
welcome dilemma of introducing novel vaccines to
already full vaccination schedules. Consequently,
some health authorities have responded to the infec-
tious disease epidemiology within their region by
including new vaccines in their immunization sche-
dules. Examples from the EPI are universal vaccina-
tion programs against invasive Hib disease and
regional programs against yellow fever or Japanese
encephalitis. Some countries in Asia have adopted
Japanese encephalitis virus vaccination during child-
hood, and this practice may expand.87
Likewise, some industrialized countries have
recently added the hepatitis A virus vaccine, the
VZV vaccine, or the S. pneumoniae CPS—conjugatevaccine to paediatric immunization schedules. In
addition, children in other industrialized countries
now routinely receive a N. meningitidis serogroup C
CPS—carrier protein conjugate vaccine,83 and pae-
diatric vaccination schedules throughout the world
might eventually include immunization against the
prevalent serogroups of N. meningitidis.88
Handling the inevitably complex assortment of
novel vaccine associations requires inventiveness.
Accordingly, efforts intensify to streamline the vac-
cination calendar. As noted, the industrialized world
tends to simplify paediatric immunization schedules
by replacing associations of different vaccines with
combination vaccines.89,90 For instance, children
may receive a five- or a six-component paediatric
vaccine that combines DTP (whole-cell or acel-
lular pertussis), IPV, HBV, and Hib vaccines (e.g.
DTP—IPV—HBV, DTP—IPV—Hib, or DPT—IPV—HBV—
Hib).91,92
There are other approaches to dealing with new
vaccine associations, which include accelerated
vaccination schedules, intercalation of new vacci-
nation visits between established immunization ses-
sions, dropping a vaccine dose from an established
schedule, or substituting non-parenteral modes of
administration to replace the customary injec-
tion(s). Ultimately, the goal of the EPI remains an
association of vaccines given by mouth during early
infancy to confer lifelong protection.93,94
This review of the literature on concomitant
immunizations, which is based on historical and
public health perspectives, suggests that some pos-
sible combination vaccines deserve reconsideration
(Table 5). Of note, regional or international health
authorities charged with serving the health needs of
children in developing countries might find any of
the following attractive: a measles virus vaccine—Japanese encephalitis
virus combination vaccine (for children in
affected regions of Asia); a measles virus vaccine—yellow fever virus com-
bination vaccine (for infants in affected regions of
Latin America and Africa); or a DTwcP-IPV—rabies virus combination vaccine
(for infants in affected regions worldwide).Since the Hib vaccine is being added to the DTP-
based paediatric combination vaccines, any paedia-
tric immunization program might increase the need
to integrate other bacterial meningitis/bacterial
pneumonia vaccines based on capsular polysacchar-
ide-carrier protein conjugate vaccines such as those
against S. pneumoniae (at least 7 serotypes) and
against N. meningitidis (ultimately, serogroups A,
C, W-135, and Y).
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vaccine, there are also drawbacks. Negative inter-
ference may diminish the protective immune
response to one or more of the components in a
candidate vaccine, thereby prolonging the efforts
needed for clinical development of the final vaccine.
Combination vaccines are more prone to shortage
due to their complex nature and the increased risk of
a batch not passing one of the numerous tests in
vaccine control. Combination vaccines may lead to
shortages of the monovalent vaccines in the combi-
nations; furthermore, monovalent vaccines may not
beproducedany longerdue to limiteddemand.These
consequences may cause problems in industrialized
countries and in developing countries.
While any vaccine candidate must be judged
against contemporary standards of safety, immuno-
genicity, and efficacy, some of the described vaccine
associations from the literature might still become
new combination vaccines. Beyond the enormous
resources required, other crucial factors are likely
to effect development, namely the perceived
necessity of the combination, and its cost-effective-
ness.95—97
In spite of such challenges, some of the vaccine
associations explored in the past warrant reconsi-
deration as targets for new combination vaccine
development.
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